Zimmer Biomet account plan
global medical technology leader
At a glance
Zimmer Biomet is a U.S. orthopedic medical technology company (knees, hips, S.E.T., ROSA robotics) with FY2025 net sales of $8,231.5 million.
Zimmer Biomet designs, manufactures and markets orthopedic reconstructive products (knees, hips), sports medicine, biologics, extremities and trauma, craniomaxillofacial and thoracic (CMFT) products, bone cement, surgical products and the ZBEdge digital and robotic platform, including the ROSA Robot. Its customers are orthopedic surgeons, neurosurgeons, hospitals, ambulatory surgery centers, stocking distributors and group purchasing organizations; consignment sales were approximately 85% of net sales in 2025. Its history dates to 1927 in Warsaw, Indiana. In FY2025 net sales were $8,231.5 million (+7.2%) and net earnings $705.1 million, with about 17,000 employees (7,000 in the U.S.) at December 31, 2025. Main competitors named are Johnson & Johnson MedTech, Stryker and Smith & Nephew.
Business units
Americas
about 62.5% of FY2025 net sales ($5,144.6 million)Largest regional segment, with the U.S. approximately 95% of the region's net sales in 2025. Sells through GPO and managed care contracts; the U.S. sales force is being converted from independent agents to employees. Segment margin fell to 51.4% from 53.7% in FY2025 on manufacturing costs and Paragon 28's lower margin; led by Kevin Thornal, Group President, Global Businesses and the Americas.
EMEA
about 22.2% of FY2025 net sales ($1,828.8 million)France, Germany, Italy, Spain and the UK were approximately 50% of the region's net sales in 2025; sold through direct sales associates, commissioned agents and independent distributors, mostly to government-sponsored healthcare. Segment margin was 32.5% in FY2025 (35.1% the year before). Led by Wilfred van Zuilen, Group President EMEA.
Asia Pacific
about 15.3% of FY2025 net sales ($1,258.1 million)Japan is the largest market, approximately 50% of the region's net sales in 2025, followed by China, Australia, Korea and others, served through dealers acting as order agents. Margin fell to 35.5% from 38.7% in FY2025; the company is transforming its distributor network and go-to-market model in China. Led by Sang Yi, Group President Asia Pacific.
Strategic priorities
- U.S. sales force conversion (Project Optima)
- Converting the U.S. sales force from independent representatives to a dedicated, specialised organisation, with completion targeted for the end of 2027. By Q3 2026 over 75% of the U.S. force was fully dedicated, three quarters into an eight-quarter journey, with 200 tech reps being added.
- Fix knees through execution and robotics
- Knees fell 3.1% in Q3 2026, with about 90% of the underperformance attributed to commercial execution. The plan combines new incentive plans and leadership with innovation: ROSA Optimize, the TMINI partnership and Monogram, whose fully autonomous version could launch in the first half of 2027.
- Shift the mix to faster-growing markets
- Management aims for a weighted average market growth rate (WAMGR) of 5%-6% by the end of the decade, by moving 85% to 90% of R&D into markets growing more than 5-6% and through M&A. Over 50 new products are expected in the next 36 months.
- Cost and operating efficiency
- The 2025 Restructuring Plan targets about $175 million of gross annual pre-tax opex savings vs 2024 by end-2027. Opex at about 46% of sales is to be addressed through AI, shared services and a global capability center in India.
- M&A from 2027
- After a 2026 focused on buybacks, deals of up to $2 billion each in higher-growth recon, S.E.T. and adjacencies such as the ASC environment, immediately revenue and WAMGR accretive and EPS accretive by year two.
Latest results
In Q3 2026 (quarter to September 30, 2026) net sales were $2,062.9 million, +3.1% reported and +3.7% constant currency; nine-month sales were $6,326.6 million (+5.7%). Hips grew 6.0%, S.E.T. 6.8% and Technology & Data, Bone Cement and Surgical 11.9%, while Knees fell 3.1% on the U.S. sales force transition, competition and the distributor transition in China. Q3 net earnings were $191.6 million vs $230.9 million, and operating profit was 14.9% of sales vs 17.6% a year earlier. The 2026 outlook was raised to net sales growth of 4.4% to 4.9%, organic constant-currency growth of 3% to 3.5% and adjusted EPS of $8.50 to $8.60.
Investments and deals
- Paragon 28 and Monogram acquisitions
- Paragon 28 (foot and ankle) acquired April 21, 2025 and Monogram Technologies (robotics) on October 7, 2025; $1,393.2 million was paid for the two in 2025. Paragon 28 grew over 18% in Q3 2026.
- Three 2026 acquisitions
- Iovera (non-surgical pain management, July 31, 2026, $74.6 million cash), Monteris Medical (laser therapy for brain tumors and epilepsy, August 11, 2026, $193.3 million cash) and Alafair Biosciences (soft-tissue protection device, August 24, 2026, $112.6 million cash), each with contingent payments.
- Manufacturing network
- A Manufacturing Network Optimization Plan started in September 2026 (about $60 million of exit costs by end-2028) consolidates U.S. sites into Warsaw, Indiana; a new manufacturing facility is under construction in Costa Rica.
- Musculoskeletal investment fund
- Commitment of up to $300 million to a fund focused on musculoskeletal and rheumatologic innovations, as exclusive orthopedic investor in the Deerfield Management and HSS Mobility Revolution Fund.
- Share buybacks
- A $1.5 billion buyback was authorised on February 9, 2026; $579.3 million of shares were repurchased in the first nine months of 2026, with $924.7 million left.
Challenges and risks
- Sales force transition risk
- The conversion is now early in its higher-risk third stage; the 10-K names loss of distributors and reps to competitors, coverage gaps and lower sales as risks.
- China distributor consolidation
- The China distributor transition weighs on growth (roughly 50 bp for 2026); China is 2% of revenue and 1% of EBITDA, and displaced distributors have raised legal claims.
- Margin pressure
- Adjusted operating margin was 25.1% in Q3 2026, down 140 bp on U.S. commercial investment; pricing was a 70 bp headwind.
- Debt and tariffs
- Debt was $7,504.2 million at September 30, 2026; U.S. tariffs and inventory charges on products to be discontinued by 2032 (about $170 million) cut FY2025 net earnings.
- Regulatory transition
- MDD-certified products must move to EU MDR by December 2027 or 2028; FDA compliance and healthcare cost containment are listed risks.
What leadership says
“we are no longer just a knee company”
“This is not a cost-savings strategy... This is a growth strategy. We want to have the best sales force in orthopedics”
“We don't call ourselves a robotic company. We call ourselves a technology company.”
“Our boldest chapter remains ahead”
Where a supplier can help
- Sales enablement for a converted U.S. force
- Tied to Project Optima: a sales force moving from independent reps to employees, with 200 tech reps being added and new incentive plans, needs onboarding, training, compensation and CRM tooling.
- AI and process re-engineering
- Tied to the opex efficiency priority: AI partners, shared services, demand planning, customer service and a global capability center in India are the named levers.
- Manufacturing consolidation support
- Tied to the Manufacturing Network Optimization Plan and the Costa Rica facility: equipment, automation and transfer services for sites consolidating into Warsaw and lower-cost geographies.
- Acquisition integration
- Tied to Paragon 28, Monogram and the three 2026 acquisitions, with more M&A planned from 2027: integration of systems, supply chains and commercial teams.
- Regulatory compliance capacity
- Tied to the EU MDR transition deadline of December 2027 or 2028 and FDA filings such as Monogram's 510(k).
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Zimmer Biomet?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for fiscal year 2025
- Zimmer Biomet is a global medical technology company (history dating to 1927, Warsaw, Indiana) that designs, manufactures and markets orthopedic reconstructive products (knees, hips), sports medicine, biologics, extremities and trauma, CMFT, bone cement, surgical products and the ZBEdge digital/robotic platform (ROSA Robot).
- FY2025 net sales were $8,231.5 million, up 7.2% (Paragon 28 acquisition +2.5%, FX +0.8%); United States $4,764.0 million (+7.3%), International $3,467.5 million (+7.0%).
- By product category: Knees $3,322.3 million (+4.7%), Hips $2,093.5 million (+4.7%), S.E.T. $2,150.2 million (+15.2%), Technology & Data, Bone Cement and Surgical $665.6 million (+4.0%).
- Net earnings fell to $705.1 million from $903.8 million, hit by ~$170 million of inventory and instrument charges on product lines to be discontinued by 2032, acquisition costs (Paragon 28, Monogram), U.S. tariffs and investments in direct-to-patient marketing, medical education and IT.
- Three regional operating segments: Americas ($5,144.6 million sales, 51.4% segment margin), EMEA ($1,828.8 million, 32.5%), Asia Pacific ($1,258.1 million, 35.5%).
- Strategic moves: Paragon 28 (foot and ankle) acquired April 21, 2025; Monogram Technologies (robotics) acquired October 7, 2025; a multi-year initiative to convert substantial portions of the U.S. sales force from independent agents to employees and to specialise it by product category; go-to-market changes in China and other markets.
- 2026 outlook in the 10-K: net sales growth of 2.5% to 4.5%, operating profit to increase; a 2025 Restructuring Plan targets ~$175 million of gross annual pre-tax opex savings vs the 2024 baseline by end-2027.
- About 17,000 employees (7,000 in the U.S.), ~2,000 in R&D, ~6,000 in manufacturing; outstanding debt $7,519.1 million at year-end; competitors named: Johnson & Johnson MedTech, Stryker and Smith & Nephew.
- Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 (quarter to September 30, 2026) net sales $2,062.9 million, +3.1%; nine months $6,326.6 million, +5.7% (Paragon 28 added 1.5% to nine-month growth).
- Q3 by category: Knees $767.5 million (-3.1%), Hips $536.5 million (+6.0%), S.E.T. $578.3 million (+6.8%), Technology & Data, Bone Cement and Surgical $180.6 million (+11.9%, on ROSA Robot and bone cement).
- Knees fell because of the U.S. sales force transition and competition and the distributor transition in China; global selling prices were a 0.7% headwind.
- Q3 net earnings $191.6 million (vs $230.9 million); nine months $628.1 million (vs $565.8 million), helped by about $30 million of probable U.S. tariff refunds.
- 2026 outlook raised to net sales growth of 4.4% to 4.9%; operating profit expected to increase despite investment in the U.S. commercial sales channel.
- Three 2026 acquisitions: Iovera (non-surgical pain management, July 31), Monteris Medical (laser therapy for brain tumors and epilepsy, August 11) and Alafair Biosciences (soft-tissue protection device, August 24).
- New Manufacturing Network Optimization Plan (September 2026, ~$60 million exit costs by end-2028); new manufacturing facility under construction in Costa Rica; commitment of up to $300 million to a musculoskeletal investment fund.
- Debt $7,504.2 million; $579.3 million of shares repurchased in nine months; $924.7 million left under the buyback.
- Q3 2026 earnings call transcript
- Q3 2026 sales of 2,063,000,000 dollars, +3.1% reported and +3.7% constant currency; 4.7% excluding the China distributor consolidation, described by Ivan Tornos as a one-time 2026 headwind.
- 2026 organic constant-currency growth guidance raised to 3% to 3.5% and adjusted EPS to $8.50 to $8.60; reported sales growth now 4.4% to 4.9%.
- Tornos: "we are no longer just a knee company" - global knees are roughly a third of sales and U.S. knees around 20%; two-thirds of the book grew upper single or double digits.
- Hips +7% constant currency (Z1 stem over 50% of U.S. hip stems); S.E.T. +7.1% with Paragon 28 up over 18%; Technology & Data, Bone Cement and Surgical +13%, U.S. technology and data up over 30%.
- Knees -2.6%: U.S. sales force transition and competition; about 90% of the knee underperformance is attributed to commercial execution.
- Monogram 510(k) filing expected very soon; a fully autonomous version could launch in the first half of 2027 instead of 2028; plan to hire at least 225 robotic sales specialists.
- U.S. sales force conversion ("Project Optima", led by Todd Baker): over 75% of the U.S. force now fully dedicated, three quarters into an eight-quarter journey; now in the higher-risk third stage.
- Opex at about 46% of sales leaves room for improvement: manufacturing consolidation into Warsaw, AI, a global capability center in India; M&A up to $2 billion per deal from 2027.
- Q2 2026 earnings call transcript
- Q2 2026 net sales of $2.177 billion, +4.8% reported and +4% organic constant currency (U.S. +4.6%, international +3.1%); adjusted EPS $2.07.
- 2026 organic constant-currency guidance raised to 2.25%-3.25% (from 1%-3%) and adjusted EPS to $8.47-$8.59; reported growth 3.9%-4.9%.
- Hips +5.1% on the "hip triple play" (Z1 over 40% of U.S. hip systems, HAMMR over 25% of U.S. primary hip cases, OrthoGrid); iodine-coated hip in Japan exceeding expectations with a 40% price premium.
- Technology and data, bone cement and surgical +21.5%; U.S. technology sales up 53% with record capital sales (ROSA with OptimiZe, TMINI) and the next-generation ROSA Shoulder launch.
- U.S. sales force transition to a dedicated, specialised organisation to be completed by end-2027; 200 tech reps being added; top six independent distributors locked in; "This is not a cost-savings strategy... This is a growth strategy."
- Over 50 new products expected in the next 36 months; Monogram 510(k) filing anticipated in the very near future; exclusive orthopedic investor in the Deerfield/HSS Mobility Revolution Fund.
- M&A criteria: up to $2 billion, immediately revenue and WAMGR accretive, EPS accretive by year two, double-digit ROIC by year five; aspiration of a 5%-6% WAMGR by the end of the decade.
- China is 2% of revenue and 1% of EBITDA and declining about 20% this year; CFO search under way with Paul Stellato as interim CFO.
Questions about Zimmer Biomet
What does Zimmer Biomet do?
It designs, manufactures and markets orthopedic products (knees, hips, sports medicine, extremities, trauma, CMFT), bone cement, surgical products and the ZBEdge robotic and digital platform, sold to surgeons, hospitals and ambulatory surgery centers.
What is Zimmer Biomet's revenue?
FY2025 net sales were $8,231.5 million, up 7.2%. In the first nine months of 2026 net sales were $6,326.6 million (+5.7%), and 2026 net sales growth guidance is 4.4% to 4.9%.
How many employees does Zimmer Biomet have?
About 17,000 at December 31, 2025, of which about 7,000 in the U.S., about 2,000 in R&D and about 6,000 in manufacturing.
Who leads Zimmer Biomet?
Ivan Tornos is Chairman, President and CEO (CEO since August 2023, Chairman since May 2025); Paul Stellato is interim CFO while a CFO search is under way.
What is Zimmer Biomet's strategy?
Converting the U.S. sales force to a dedicated, specialised organisation, fixing knees with robotics such as ROSA and Monogram, shifting R&D and M&A toward faster-growing markets, and cutting costs through restructuring and manufacturing consolidation.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)